Role of molecular imaging in the detection of localized prostate cancer

Samuel J Galgano; Janelle T West; Soroush Rais-Bahrami

doi:10.1177/17562872221105018

Role of molecular imaging in the detection of localized prostate cancer

Ther Adv Urol. 2022 Jun 21:14:17562872221105018. doi: 10.1177/17562872221105018. eCollection 2022 Jan-Dec.

Authors

Samuel J Galgano¹, Janelle T West², Soroush Rais-Bahrami²

Affiliations

¹ Department of Radiology, The University of Alabama at Birmingham, 619 19th Street South, JT J779, Birmingham, AL 35294, USA.
² Department of Radiology, The University of Alabama at Birmingham, Birmingham, AL, USA.

Abstract

Molecular imaging of prostate cancer continues to grow, with recent inclusion of several positron emission tomography (PET) radiotracers into the recent National Comprehensive Cancer Network guidelines and the US Food and Drug Administration approval of prostate-specific membrane antigen (PSMA)-targeted radiotracers. While much of the work for many of these radiotracers is focused on systemic staging and restaging in both newly diagnosed high-risk prostate cancer and biochemically recurrent disease patients, the potential role of molecular imaging for the detection of localized prostate cancer has not yet been fully established. The primary aim of this article will be to present the potential role for molecular imaging in the detection of localized prostate cancer and discuss potential advantages and disadvantages to utilization of both PET/computed tomography (CT) and PET/magnetic resonance imaging (MRI) for this clinical indication of use.

Keywords: cancer staging; fusion biopsy; positron emission tomography (PET); prostatic adenocarcinoma.

Publication types

Review